e-learning
resources
Copenhagen 2005
Tuesday 20.09.2005
Treatment of pulmonary arterial hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH)
P. Corris, G. Burgess, T. Parpia, R. Barst (Newcastle upon Tyne, Sandwich, United Kingdom; New York, United States Of America)
Source:
Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Session:
Treatment of pulmonary arterial hypertension
Session type:
Oral Presentation
Number:
3128
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Corris, G. Burgess, T. Parpia, R. Barst (Newcastle upon Tyne, Sandwich, United Kingdom; New York, United States Of America). Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH). Eur Respir J 2005; 26: Suppl. 49, 3128
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
Source: Eur Respir J 2011; 37: 70-77
Year: 2011
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Source: Eur Respir J 2006; 28: 1195-1203
Year: 2006
The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study
Source: Eur Respir J 2006; 28: 138-143
Year: 2006
Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension
Year: 2009
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Longer-term survival in paediatric patients with idiopathic or familial pulmonary arterial hypertension treated with bosentan
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009
Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases
Year: 2016
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 92-98
Year: 2009
Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020
Year: 2020
Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016
A 1-year evolution of pulmonary artery pressure in the patients treated with various therapeutic methods after acute pulmonary embolism (PE). Its impact on the chronic thromboembolic pulmonary hypertension (CTEPH) development
Source: Eur Respir J 2003; 22: Suppl. 45, 221s
Year: 2003
Is there a fixed relationship between the mean and systolic pulmonary artery pressures in idiopathic pulmonary arterial hypertension (IPAH) and proximal chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Annual Congress 2009 - Pulmonary embolism
Year: 2009
The effect of 12 months Bosentan treatment on congenital heart disease associated pulmonary arterial hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 425s
Year: 2006
Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension
Year: 2019
A critical analysis of survival in pulmonary arterial hypertension
Source: Eur Respir Rev 2012 21:218-222
Year: 2012
Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy?
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy
Source: Eur Respir J 2005; 26: Suppl. 49, 476s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept